Next Generation Percutaneous AV Fistula Creation
Vascular Access Simplified
The Velocity™ Percutaneous Arterio-Venous Fistula System
About the Velocity™ pAVF System
Despite clear benefits of initiating hemodialysis with an arteriovenous fistula–including lower mortality, less reinterventions and lower health care costs—few patients in the U.S do so. The Velocity pAVF is the next generation of vascular access systems that will address patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for reintervention.
Why are we developing the Velocity™ System?
-
There are nearly 500,000 individuals currently on hemodialysis (HD) in the U.S. [1]
-
62.6% of patients on HD dialyze via an arteriovenous (AV) fistula, the preferred vascular access option for HD patients. [1]
-
AVFs can be created surgically or by using newer minimally invasive percutaneous techniques.
-
Percutaneous AV fistulas (pAVfs) are less invasive, have a faster recovery time, have a reduced risk of complications, and can often be cannulated sooner than a surgical AVF. [2]
-
Studies have shown that reintervention rates for currently available pAVF procedures can range from 20% to 50% with one or more reinterventions often necessary to achieve adequate fistula maturation prior to their use for hemodialysis. [3]
-
The Velocity System is designed to provide an opportunity to streamline the process to create functional dialysis access without follow up interventions.
[1] United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022.
[2] Wasse H. Place of Percutaneous Fistula Devices in Contemporary Management of Vascular Access. Clin J Am Soc Nephrol. 2019 Jun 7;14(6):938-940. doi: 10.2215/CJN.00980119.
[3] Sun JB, et al. Percutaneous endovascular arteriovenous fistula: A systematic review and meta-analysis. Front Cardiovasc Med. 2022 Sep 6;9:978285. doi: 10.3389/fcvm.2022.978285.
The Venova Velocity System is currently under development and is not approved for sale in any country.
About Us
Venova Medical, Inc. is a privately held company addressing the challenges associated with providing optimal vascular access for patients that need hemodialysis. The company has developed the Velocity System, a next generation percutaneous AVF technology designed to reduce the need for reinterventions to achieve fistula maturation and improve vascular access outcomes while reducing costs.
Our Team
The Venova Medical team is comprised of individuals who bring a wealth of experience that covers both medical device development and clinical expertise.
Keif Fitzgerald
VP of Engineering
Erik van der Burg
Co-Founder, Director & CEO
Robert Nardelli
VP of Quality & Regulatory Affairs
Shant Vartanian, MD
Co-Founder & Director
Michael Wallace
Director
Our Team
The Venova Medical team is comprised of individuals who bring a wealth of experience that covers both medical device development and clinical expertise.
Erik van der Burg
Co-Founder, Director & CEO
Shant Vartanian, MD
Co-Founder & Director
Keif Fitzgerald
VP of Engineering
Robert Nardelli
VP of Quality & Regulatory Affairs
Michael Wallace
Director
Our Investors
News and Events
ASDIN 20th Annual Scientific Meeting | February 23-25, 2024 | New Orleans, Louisiana
Venova Medical will be attending the 20th Annual Scientific Meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN) being held from February 23rd to 25th in New Orleans, Louisiana. Additionally, Robert Shahverdyan, MD, Head of Vascular...
Secondary interventions to assist pAVF maturation remain commonplace for current endoAVF devices
While currently available percutaneous arteriovenous fistula (pAVF) devices have demonstrated a high rate of technical procedural success, secondary interventions are often required to achieve fistula maturation with these devices. CLICK HERE to read an excellent...
Robert Shahverdyan, MD presents insights from initial clinical experience with the Velocity System during Charing Cross (CX) Symposium
During the recent Charing Cross (CX) International Symposium held in London, Robert Shahverdyan, MD detailed the challenges associated with the use of current endovascular arteriovenous fistula (endoAVF) devices and provided insights from his clinical experience with...